As of close of business last night, Pacific Biosciences of California Inc’s stock clocked out at $3.17, down -6.21% from its previous closing price of $3.38. On the day, 8692016 shares were traded.
Ratios:
To gain a deeper understanding of PACB’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 7.21 and its Current Ratio is at 7.81. In the meantime, Its Debt-to-Equity ratio is 1.33 whereas as Long-Term Debt/Eq ratio is at 1.32.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Stephens on December 14, 2023, initiated with a Overweight rating and assigned the stock a target price of $11.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Mar 06 ’24 when Meline David W bought 40,000 shares for $4.40 per share. The transaction valued at 176,160 led to the insider holds 40,000 shares of the business.
HENRY CHRISTIAN O sold 14,177 shares of PACB for $69,056 on Mar 04 ’24. The insider now owns 2,596,670 shares after completing the transaction at $4.87 per share. On Mar 04 ’24, another insider, Van Oene Mark, who serves as the insider of the company, sold 9,186 shares for $4.87 each. As a result, the insider received 44,745 and left with 1,668,826 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 4.24 while its Price-to-Book (P/B) ratio in mrq is 1.21.
Stock Price History:
Over the past 52 weeks, PACB has reached a high of $14.55, while it has fallen to a 52-week low of $3.21.
Shares Statistics:
A total of 267.74M shares are outstanding, with a floating share count of 251.67M. Insiders hold about 6.08% of the company’s shares, while institutions hold 98.34% stake in the company.
Earnings Estimates
As of right now, Aurora Cannabis Inc. analysts gave their recommendation on the stock of the company. The consensus estimate for the next quarter is $3.17, with high estimates of $2.23 and low estimates of $162.76.
Analysts are recommending an EPS of between $Healthcare and $Industrials for the fiscal current year, implying an average EPS of $Healthcare.
